TY - JOUR
T1 - A factorial experiment grounded in the multiphase optimization strategy to promote viral suppression among people who inject drugs on the Texas-Mexico border
T2 - a study protocol
AU - Sauceda, John A.
AU - Lechuga, Julia
AU - Ramos, Maria Elena
AU - Puentes, Jorge
AU - Ludwig-Barron, Natasha
AU - Salazar, Jorge
AU - Christopoulos, Katerina A.
AU - Johnson, Mallory O.
AU - Gomez, David
AU - Covarrubias, Rogelio
AU - Hernandez, Joselyn
AU - Montelongo, David
AU - Ortiz, Alejandro
AU - Rojas, Julian
AU - Ramos, Luisa
AU - Avila, Itzia
AU - Gwadz, Marya V.
AU - Neilands, Torsten B.
N1 - Funding Information:
Funding was provided by the National Institute on Drug Abuse, award number R01 DA053659.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/2
Y1 - 2023/2
N2 - Background: People who inject drugs living with HIV (PWIDLH) suffer the lowest rates of HIV viral suppression due to episodic injection drug use and poor mental health coupled with poor retention in HIV care. Approximately 44% of PWIDLH along the US-Mexico border are retained in care and only 24% are virally suppressed. This underserved region faces a potential explosion of transmission of HIV due to highly prevalent injection drug use. This protocol describes an optimization trial to promote sustained viral suppression among Spanish-speaking Latinx PWIDLH. Methods: The multiphase optimization strategy (MOST) is an engineering-inspired framework for designing and building optimized interventions and guides this intervention. The primary aim is to conduct a 24 factorial experiment in which participants are randomized to one of 16 intervention conditions, with each condition comprising a different combination of four behavioral intervention components. The components are peer support for methadone uptake and persistence; behavioral activation therapy for depression; Life-Steps medication adherence counseling; and patient navigation for HIV care. Participants will complete a baseline survey, undergo intervention, and then return for 3-,6-,9-, and 12-month follow-up assessments. The primary outcome is sustained viral suppression, defined as viral loads of < 40 copies per mL at 6-,9-, and 12-month follow-up assessments. Results will yield effect sizes for each component and each additive and interactive combination of components. The research team and partners will make decisions about what constitutes the optimized multi-component intervention by judging the observed effect sizes, interactions, and statistical significance against real-world implementation constraints. The secondary aims are to test mediators and moderators of the component-to-outcome relationship at the 6-month follow-up assessment. Discussion: We are testing well-studied and available intervention components to support PWIDLH to reduce drug use and improve their mental health and engagement in HIV care. The intervention design will allow for a better understanding of how these components work in combination and can be optimized for the setting. Trial registration: This project was registered at clinicaltrials.gov (NCT05377463) on May 17th, 2022.
AB - Background: People who inject drugs living with HIV (PWIDLH) suffer the lowest rates of HIV viral suppression due to episodic injection drug use and poor mental health coupled with poor retention in HIV care. Approximately 44% of PWIDLH along the US-Mexico border are retained in care and only 24% are virally suppressed. This underserved region faces a potential explosion of transmission of HIV due to highly prevalent injection drug use. This protocol describes an optimization trial to promote sustained viral suppression among Spanish-speaking Latinx PWIDLH. Methods: The multiphase optimization strategy (MOST) is an engineering-inspired framework for designing and building optimized interventions and guides this intervention. The primary aim is to conduct a 24 factorial experiment in which participants are randomized to one of 16 intervention conditions, with each condition comprising a different combination of four behavioral intervention components. The components are peer support for methadone uptake and persistence; behavioral activation therapy for depression; Life-Steps medication adherence counseling; and patient navigation for HIV care. Participants will complete a baseline survey, undergo intervention, and then return for 3-,6-,9-, and 12-month follow-up assessments. The primary outcome is sustained viral suppression, defined as viral loads of < 40 copies per mL at 6-,9-, and 12-month follow-up assessments. Results will yield effect sizes for each component and each additive and interactive combination of components. The research team and partners will make decisions about what constitutes the optimized multi-component intervention by judging the observed effect sizes, interactions, and statistical significance against real-world implementation constraints. The secondary aims are to test mediators and moderators of the component-to-outcome relationship at the 6-month follow-up assessment. Discussion: We are testing well-studied and available intervention components to support PWIDLH to reduce drug use and improve their mental health and engagement in HIV care. The intervention design will allow for a better understanding of how these components work in combination and can be optimized for the setting. Trial registration: This project was registered at clinicaltrials.gov (NCT05377463) on May 17th, 2022.
KW - ART adherence
KW - Behavioral activation therapy (BAT)
KW - Factorial experiment
KW - HIV care continuum
KW - HIV viral load suppression
KW - Life-steps
KW - Medication-assisted treatment (MAT)
KW - Multiphase optimization strategy (MOST)
KW - Patient navigation
KW - U.S.-Mexico Border
UR - http://www.scopus.com/inward/record.url?scp=85147892673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147892673&partnerID=8YFLogxK
U2 - 10.1186/s12889-023-15172-2
DO - 10.1186/s12889-023-15172-2
M3 - Article
C2 - 36765309
AN - SCOPUS:85147892673
SN - 1471-2458
VL - 23
JO - BMC public health
JF - BMC public health
IS - 1
M1 - 307
ER -